A machine learning–based tool accurately predicted risk for recurrent inflammatory activity after DMT discontinuation in MS, highlighting its potential to guide personalized treatment decisions.
A new study in the Journal of Psychopharmacology questions whether psychedelics reliably enhance creative thinking, finding ...
Discover Atai Life Sciences N.V.'s 275% YTD surge, driven by innovative psychedelic therapies for TRD. Click for my ATAI ...
Lawmakers in New York are revisiting the possibility of reforming the state’s laws related to psychedelics, convening a ...
Pharmaceutical Technology on MSN
Biogen’s high-dose Spinraza turned down by FDA due to CMC troubles
Biogen's Spinraza is not the first drug to face a CMC-related rejection recently, as SMA competitor drug, apitegromab, also ...
Work on medical uses of mind-altering substances was sidelined for decades by the political backlash against drugs, a misstep ...
DMT, or dimethyltryptamine is a natural psychoactive molecule found in many plants and mammals. According to an article published in Science Advances ...
Keith Tan, [email protected], Zhuo ling Heng, [email protected], Kyla Koh, [email protected] | Iron ...
A stem cell transplant lowers the risk of PIRA in people with aggressive RRMS more effectively than standard drug therapies, ...
Alaska activists have officially launched a signature drive to place an initiative on the 2026 ballot to legalize certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback